Organogenesis Inc. was originally founded in 1985 as a spin-off of technology developed at the Massachusetts Institute of Technology (MIT). In 2017, Organogenesis acquired NuTech Medical, which further expanded our wound care portfolio and introduced product solutions for the surgical and sports medicine markets.
Today, Organogenesis has more than 900 employees worldwide and is led by a management team of talented individuals with more than 100 years of collective regenerative medicine experience.
1998: FDA approves Apligraf® for the treatment of venous leg ulcers
2000: FDA approves Apligraf® for the treatment of diabetic foot ulcers
2004: Launch of full USA sales and marketing organization
2006: European office established in Switzerland
2014: Acquires Dermagraft® for treatment of chronic diabetic foot ulcers
2015: Launches new PuraPly® product line
2017: Acquires NuTech Medical and expands product portfolio to include Surgical and Sports Medicine
2018: Organogenesis becomes a public company through merger with Avista Healthcare
2020: Acquires CPN Biosciences